Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T14:22:39.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the removal of detailed study descriptions and inclusion/exclusion criteria for a clinical trial, while retaining the study's collaborators and revision information.
    Difference
    19%
    Check dated 2025-04-16T10:32:10.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 20, 2025.
    Difference
    0.3%
    Check dated 2025-04-09T04:51:59.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The page has been updated to reflect the termination of a study involving Fruquintinib and Tislelizumab, with new dates and availability information for these drugs in the U.S.
    Difference
    4%
    Check dated 2025-03-25T13:22:44.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-03-03T22:31:00.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T14:43:29.000Z thumbnail image

Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.